PROGRAMMA.ANN.2016.ver.07.del 26 Gen 2016.final · Aula Magna, Università di Roma “Sapienza”...

A I S F ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998 Iscritta nell’Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011

Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011

49th AISF Annual Meeting Aula Magna, Università di Roma “Sapienza” ‐ P. le A. Moro, 5

Rome, February 18th‐19th, 2016

S C I E N T I F I C P ROG R AMME

Thursday, February 18th

08.30‐10.00 Selected Oral Communications Chairpersons: P. Andreone, Bologna M. Fasano, Foggia

08.30‐08.45 MiR‐B‐Index: a candidate bio‐marker to identify the immune control of HBV infection in chronic hepatitis B patients treated with nucleos(t)ide‐analogues

D. Cavallone, F. Oliveri, P. Colombatto, B. Coco, V. Romagnoli, L. Surace, S. Fabiani, G. Ricco, F. Moriconi, F. Bonino, M.R. Brunetto ‐ Pisa

08.45‐09.00 Clinical relevance of accurate HCV genotype and subtype assignment by ns3/ns5a/ns5b direct sequencing in the era of new direct acting antiviral agents

M. Aragri, V.C. Di Maio, D. Di Paolo, V. Cento, F. De Leonardis, L. Gianserra, M. Tontodonati, V. Micheli, S. Landonio, A. Manunta, A. Bertoli, M Ciotti, F.P. Antonucci, R. Campoli, K. Yu La Rosa, F. Deodati, I. Lenci, S. Francioso, L.A. Nicolini, S. Marenco, E. Teti, L. Lambiase, M. Milana, I. Maida, A. Di Biagio, A. Pellicelli, L. Nosotti, S. Grieco, P. Cacciatore, D. Romagnoli, M. Siciliano, G. D’Ettorre, S. Babudieri, M. Lichtner, U. Vespasiani‐Gentilucci, M. Romano, C. Sarrecchia, A. Grieco, F. Morisco, C. Mastroianni, J. Vecchiet, M. Puoti, E. D’Amico, N. Caporaso, A. Gasbarrini, S. Bruno, C. Magni, M.S. Mura, G. Taliani, A. Picciotto, G. Rizzardini, M. Andreoni, C. Pasquazzi, G. Parruti, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein Rome, Pescara, Milan, Sassari, Genoa, Baggiovara (MO), Latina, Naples, Chieti, Penne (PE), Rozzano (MI)

09.00‐09.15 Treatment failure to first‐Line direct antiviral (DAA) in HCV‐related advanced liver disease: an Italian real‐life urban setting

D. Di Paolo, P. Rossi, I. Lenci, M. Milana, C. Masetti, F. Santopaolo, R. Lionetti, G. D’Offizi, A. Pellicelli, L. Fondacaro, M. Siciliano, V. Gerardi, F. Chiesara, A. Moretti, F. Ceccherini‐Silberstain, V. Cento, C.F. Perno, M. Angelico ‐ Rome

09.15‐09.30 The combination of IFN‐lambda‐4 and HLA‐DPB1 polymorphisms accurately predict HBsAg loss in IFN treated genotype D HBeAg‐negative patients with chronic hepatitis B

P. Lampertico, E. Galmozzi, F. Facchetti, C. Cheroni, F. Invernizzi, V. Valveri, R. Soffredini, M. Viganò, S. Abrignani, R. De Francesco, M. Colombo ‐ Milan

09.30‐09.45 Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re‐treatment

V.C. Di Maio, V. Cento, D. Di Paolo, I. Lenci, M. Aragri, G. Verucchi, M. Melis, A. Bertoli, F.P. Antonucci, S. Francioso, A. Pellicelli, V. Calvaruso, C. Pasquazzi, D. Romagnoli, K. Yu La Rosa, R. Campoli, M. Biolato, J. Vecchiet, M.C. Sorbo, F. Morisco, M. Merli, G. Brancaccio, G.B. Gaeta, S. Brillanti, F. Donato, M. Puoti, V. Pisani, A. Grieco, N. Caporaso, M. Paoloni, S. Babudieri, M.S. Mura, A. Craxì, M. Angelico, C.F. Perno, Ceccherini‐Silberstein ‐ Rome, Bologna, Sassari, Palermo, Modena, Chieti, Naples, Milan, Catanzaro, Avezzano (AQ)

09.45‐10.00 Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice

F. Conti, A. Scuteri, G. Vitale, G. Lazzarini, A. Porro, P. Muratori, I. Serio, F. Buonfiglioli, L. Badia, A. Lanzi, M. Mastroroberto, L. Appolloni, M. Morotti, M.C. Morelli, F.G. Foschi, G. Verucchi, S. Brillanti, C. Crespi, M. Lenzi, G. Mazzella, P. Andreone ‐ Bologna, Faenza (RA)

10.00‐10.30 State‐of‐the‐Art Lecture Introduced by: A. Craxì, Palermo Multicentre real life clinical research: impact on

clinical government, health policies and health care

G.W. Ricciardi, Rome

10.30‐11.00 Coffee break and Posters view Tutors: A. Alisi, Rome ‐ M.A. Iavarone, Milan

11.00‐12.15 General Assembly II




12.15‐13.15 Selected Oral Communications Chairpersons: B. Coco, Pisa ‐ C.F. Perno, Rome 12.15‐12.30 Kidney involvement in HCV Child‐A cirrhosis D. Palazzo, E. Biliotti, F. Tinti, A. Bachetoni,

P. Perinelli, S. Grieco, A. Cappoli, M. Subic, M.D. D’Alessandro, R. Labriola, I. Umbro, P. Rucci, A.P. Mitterhofer, G.Taliani ‐ Rome, Bologna

12.30‐12.45 High SVR rates with SMV+SOF in HCV GT1 and GT4 patients with cirrhosis or advanced fibrosis: a real practice analysis from a large regional database in Tuscany, Italy

E. Salomoni, E. Gianni, L. Gragnani, F. Oliveri, M.R. Brunetto, S. Luchi, D. Bartolozzi, P. Forte, S. Sani, P. Blanc, R. Sacco, A.L. Zignego, A. De Luca, D. Tacconi, D. Aquilini, F. Menichetti, C. Catalani, C. Nencioni, P. Carrai, S. Chigiotti, P. Colombatto on behalf of Epatologi Toscani and SIMIT Toscana Florence, Pisa, Lucca, Livorna, Siena, Arezzo, Prato, Pistoia, Grosseto

12.45‐13.00 Vaccine‐escape HBsAg mutants circulating among genotype D HBV‐infected patients correlate with atypical serological profiles, high viremia and transaminases: potential impact on vaccination strategies

R. Salpini, A. Battisti, L. Colagrossi, C. Alteri, A. Bertoli, L. Fabeni, C. Sarrecchia, D. Di Carlo, M. Pollicita, M. Lichtner, C. Mastroianni, G. De Sanctis, M. Paoloni, M. Marignani, C. Pasquazzi, D. Di Paolo, N. Iapadre, T. Mari, C. Puoti, G. Parruti, S. Romano, M. Visca, I. Vecchiet, M. Andreoni, G. Cappiello, A. Spanò, M. Angelico, C.F. Perno, V. Svicher ‐ Rome, Avezzano (AQ), L’Aquila, Pescara, Grottaferrata (RM), Chieti

13.00‐13.15 HCV‐related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study

L.E. Weimer, M. Vinci, G. Borgia, M. Brunetto, L. Sturace, G.B. Gaeta, L. Chemello, A. Buggio, P. Andreone, G. Raimondo, R. Filomia, M. Persico, M. Puoti, M.G. Rumi, A. Benedetti, S. Fargion, D. Ieluzzi, G. Nardone, G. Foti, A. Ciancio, G.Taliani, E. Biliotti, S. Madonia, B. Stagno, A. Alberti, M. Massari, F. Rosina, G. Mazzella, A. Di Leo, A. Iannone, C. Ferrari, A. Orlandini, L. Gragnani, T.A. Santantonio, L. Chessa, E.M. Erne, C. Coppola, M. Andreoni, F. Baldelli, M. Mondelli, P. Blanc, A. Gasbarrini, F. D’Aversa, G. Verucchi, M. Colombo, M. Borghi, A. Craxì, S. Petta, E. Villa, O. Patti, F.P. Russo, M. Strazzabosco, A. Mallano, L. Fucili, M. Massella, L. Kondili, S. Vella, A. L. Zignego and ISS&AISF&SIMIT collaborating Group in PITER (available in www.iss.it/piter) ‐ Rome, Milan, Naples, Pisa, Padua, Bologna, Messina, Salerno, Ancona, Verona, Reggio Calabria, Turin, Palermo, Reggio Emilia, Gradenigo (TO), Bari, Parma, Florence, Foggia, Cagliari, Gragnano (NA), Perugia, Pavia, Modena, Monza (MB)

13.15‐13.45 Young Investigator Lecture

Introduced by: D. Alvaro, Rome Biliary system and liver: new insights from

immune system for understanding the natural history, therapy and outcomes

A. Lleo de Nalda, Rozzano 13.45‐14.45 Lunch break and Posters view

Tutors: M. Carbone, Rozzano ‐ S.S. Piano, Padua 14.45‐15.30 2014 AISF Fellowships Report Introduced by: A. Ciancio, Turin 14.45‐15.00 Progression of liver damage in diet‐induced NAFLD

model in zebrafish: the role of inflammation promoted by thioacetamide

F. Milosa, Modena 15.00‐15.15 Role of tryptophan metabolism via the

indoleamine 2,3‐dioxygenase (IDO) pathway in experimental steatohepatitis

A. Provenzano, Florence 15.15‐15.30 The involvement of Fas‐FasL pathway in

hepatocellular carcinoma immuno escape E. Trombetta, Milan

15.30‐16.00 State‐of‐the‐Art Lecture Introduced by: E. Bugianesi, Turin Childhood fatty liver: a tick‐time bomb for public

health V. Nobili, Rome

16.00‐16.15 Presentation of the AISF prize for the best Italian paper in 2014

Introduced by: C. Cammà, Palermo L. Valenti, Milan Gluconeogenic Signals Regulate Iron Homeostasis

via Hepcidin in Mice Gastroenterology. 2014 April; 146(4): 1060–1069.e3 C. Vecchi, G. Montosi, C. Garuti, E. Corradini,

M. Sabelli, S. Canali, A. Pietrangelo ‐ Modena 16.15‐16.45 Coffee break and Posters view Tutors: A. Alisi, Rome ‐ M.A. Iavarone, Milan 16.45‐17.15 State‐of‐the‐Art Lecture Introduced by: F. Morisco, Naples Pregnancy and the liver E. Villa, Modena




17.15‐18.30 Selected Oral Communications Chairpersons: L.S. Belli, Milan ‐ F. Trevisani, Bologna 17.15‐17.30 Influence of donor and recipient gender on liver

transplantation outcomes in Europe: a ELTR study G. Germani, A. Ferrarese, R. Adam, V. Karam,

J. O’Grady, D. Mirza, J. Klempnauer, D. Cherqui, J. Pratschke, N. Jamieson, M. Salizzoni, E. Hidalgo, J. Lerut, A. Paul, J.C.Garcia‐Valdecasas, F. San Juan Rodríguez, P. Burra, for the European Liver and Intestine Transplant Association (ELITA) ‐ Padua, Paris (France), Villejuif (France), London (UK), Birmingham (UK), Hannover (Germany), Berlin (Germany), Cambridge (UK), Turin, Leeds (UK), Brussels (Belgium), Essen (Germany), Barcelona (Spain), Valencia (Spain)

17.30‐17.45 MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver

B. Donati, P. Dongiovanni, L. Miele, C. Rosso, S. Maier, S. Petta, M. Meroni, L. De Luca, S. Grimaudo, R. Romagnoli, F. Colli, A. Craxi, A. Grieco, E. Bugianesi, S. Fargion, A.L. Fracanzani, G. Soardo, L. Valenti ‐ Milan, Rome, Turin, Udine, Palermo

17.45‐18.00 The role of mir‐124 and aurora kinase A in the multidrug resistance in HCC

P. Popović, C. Tiribelli, D. Pascut ‐ Trieste 18.00‐18.15 Ruvbl1 regulates liver glucose metabolism via the

Akt/mTOR pathway: implications for hepatocellular carcinoma progression

T. Mello, F. Zanieri, M. Materozzi, O. Bereshchenko, E. Ceni, M. Tarocchi, G. Marroncini, S. Polvani, S. Tempesti, C. Nerlov, S. Milani, A. Galli ‐ Florence, Perugia, Edinburgh (UK)

18.15‐18.30 Prognostic relevance of stage migration in patients with hepatocellular carcinoma: a multicenter cohort study

A. Vitale, F. Farinati, M. Polacco, F. Trevisani, U. Cillo. On behalf of the ITA.LI.CA study group Padua, Bologna

Friday, February 19th 08.30‐10.00 Selected Oral Communications Chairpersons: G. Addolorato, Rome S. Bellentani, Modena 08.30‐08.15 Lack of NLRP3‐Inflammasome leads to gut‐liver axis

derangement and increases hepatic injury in a mouse model of NAFLD

I. Pierantonelli, L. Agostinelli, C. Rychlicki, M. Gaggini, C. Fraumene, E.Mingarelli, C. Saponaro, V. Manghina, E. Buzzigoli, C.Pinto, L. Trozzi, S. Saccomanno, A. Benedetti, M. Marzioni, S. De Minicis, S. Uzzau, A. Gastaldelli, G. Svegliati Baroni ‐ Ancona, Pisa, Alghero, Sassari

08.15‐08.30 FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with Nonalcoholic fatty liver disease

S. Petta, L. Valenti, R.M. Pipitone, P. Dongiovanni, C. Cammà, A.L. Fracanzani, V. Di Marco, M. Milano, S. Grimaudo, S. Fargion, A. Craxì ‐ Palermo, Milan

08.30‐08.45 Hypoxia‐inducible factor‐2α affects fibrogenic progression of experimental non‐alcoholic fatty liver disease

E. Morello, S. Sutti, S. Cannito, E. Novo, C. Bocca, B. Foglia, S. Bruzzi, G.Villano, P. Pontisso, E. Bugianesi, E. Albano, M. Parola ‐ Turin, Novara, Padua

08.45‐09.00 Impact and mechanisms of insulin resistance on liver damage progression in a mouse model of non‐alcoholic steatohepatitis (NASH)

M. Meroni, P. Dongiovanni, G.A. Baselli, R. Rametta, S. Gatti, M. Maggioni, L. Valenti ‐ Milan

09.00‐09.15 High Mobility Group Box 1 (HMGB1) and Neutrophils an unexpected role in Non‐alcoholic fatty liver disease: inhibition of T cell activation and proliferation

L. Antonucci, M. Picozza, A. Renzi, E. Gaudio, C. Balsano ‐ Rome

09.15‐09.30 Adipose tissue insulin resistance is associated with macrophage activation in non‐diabetic patients with non‐alcoholic fatty liver disease

M. Marietti, C. Rosso, M. Gaggini, C. Saponaro, K. Kazankov, E. Buzzigoli, H.J. Møller, G.P. Caviglia, M.L. Abate, A. Smedile, G.M. Saracco, H. Vilstrup, J. George, H. Grønbæk, A. Gastaldelli, E. Bugianesi Turin, Pisa, Aarhus (Denmark), Westmead (Australia)

10.00‐10.30 State‐of‐the‐Art Lecture Introduced by: L. Valenti, Milan Hepatic Notch signalling, insulin resistance and non‐

alcoholic steatohepatitis U. Pajvani (New York, NY, USA)

10.30‐11.00 Coffee break and Posters view Tutors: M. Carbone, Rozzano ‐ S.S. Piano, Padua




11.00‐12.20 Symposium "National early access programs for HCV new treatments: the Italian experience"

Chairpersons: R. Bruno, Pavia M. Colombo, Milan 11.00‐11.05 Introduction M. Marzioni, Ancona

11.05‐11.25 Effects of the national program for early access to sofosbuvir therapy in Italy for patients with chronic hepatitis C in liver transplant waiting list P. Caraceni, Bologna

11.25‐11.45 Effects of the national program for early access to sofosbuvir therapy in Italy for patients with chronic hepatitis C recurring after liver transplantation

P. Toniutto, Udine

11.45‐12.05 Effects of the national program for early access to 3D therapy in Italy for patients with chronic hepatitis C

S. Petta, Palermo

12.05‐12.20 Discussion 12.20‐13.35 Selected Oral Communications Chairpersons: V. Calvaruso, Palermo L. Fabris, Padua

12.20‐12.35 Nlrp3 inflammasome activation by microbial products leads to Il‐18 synthesis and impaired epithelial barrier function in cholangiocytes

L. Maroni, L. Agostinelli, S. Saccomanno, E. Mingarelli, C. Rychlicki, S. De Minicis, J.M. Banales, A. Benedetti, G. Svegliati Baroni, M. Marzioni ‐ Ancona, Fermo, San Sebastian (Spain)

12.35‐12.50 Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro‐hemostatic imbalance and herald severe outcome in cirrhosis

V. La Mura, A. Tripodi, G. Tosetti, V. Chantarangkul, L. Baronciani, F. Peyvandi, M. Iavarone, A. Sangiovanni, M. Primignani, M. Colombo ‐ Milan

12.50‐13.05 The CXCL12/CXCR7 system mediates migration and survival of cholangiocarcinoma (CCA) cells through interaction with CXCR4 and βarrestin‐2

A. Gentilini, A. Caligiuri, M. Pastore, K. Rombouts, M. Pinzani, C. Raggi, P. Invernizzi, C. Raschioni, F. Marra ‐ Florence, London (UK), Rozzano (MI)

13.05‐13.20 The intra‐tumor heterogeneity of C19MC miRNA cluster expression mirrors the presence of the side population in HCC

F. Colombo, C. Augello, A. Terrasi, E. Trombetta, M. Maggioni, M. Baccarin, R. Silipigni, S. Guerneri, S. Bosari, L. Porretti, V. Vaira ‐ Milan

13.20‐13.35 Silencing of the focal adhesion kinase reduces hepatocellular carcinoma growth affecting enhancer of zeste homolog 2 transcription and activity

D. Gnani, S. Artuso, I. Romito, C. De Stefanis, N. Panera, A. Crudele, C. Balsano, R. Rota, V. Nobili, C. Leonetti, A. Alisi ‐ Rome

13.35‐14.35 Lunch break and Posters view Tutors: A. Alisi, Rome ‐ M.A. Iavarone, Milan 14.35‐15.35 General Assembly III 15.35‐15.50 Presentation of the AISF distinguished service award

to Prof. Mario Angelico Introduced by: M. Marzioni, Ancona Presenter: D. Alvaro, Rome 15.50‐17.20 Selected Oral Communications Chairpersons: V. La Mura, Milan ‐ O. Riggio, Rome

15.50‐16.05 Terlipressin given by continuous intravenous infusion versus terlipressin given by intravenous boluses in the treatment of hepatorenal syndrome in patients with cirrhosis: Final results of a controlled clinical study

M. Cavallin, S. Piano, S. Fasolato, A.C. Frigo, G.P. Benetti, A. Romano, F. Morando, C. Pilutti, S. Rosi, M. Tonon, M.L. Stanco, E. Gola, A. Sticca, U. Cillo, A. Gatta, P. Angeli ‐ Padua, Melegnano (MI)

16.05‐16.20 Progressive alterations of cardiopulmonary hemodynamics accompanied by increasing levels of C reactive protein (CRP) occur in patients in different stages of cirrhosis and predict death in decompensated cirrhosis

L. Turco, I. Magnani, M. Bianchini, M. Costetti, C. Caporali, E. Simonini, R. Rossi, E. Villa, F. Schepis Modena

16.20‐16.35 The TLR10 polymorphism rs4129009 is associated to poor 28‐day survival in patients with cirrhosis and acute on chronic liver failure precipitated by bacterial infection

M. Domenicali, P. Caraceni, M. Baldassarre, F. Giannone, E. Marasco, M. Pavesi, V. Mantovani, P. Angeli, A. Gerbes, R. Moreau, R. Jalan, P. Ginés, V. Arroyo, M. Bernardi for the CANONIC Study Investigators of the EASL‐CLIF Consortium Bologna, Barcelona (Spain), Padua, Munich (Germany), Paris (France), London (UK)

16.35‐16.50 Management of malnutrition in patients with cirrhosis requires a personalized educational approach

F.A. Giannone, M. Domenicali, M. Baldassarre, P. De Pasquale, S. Boffelli, M. Laggetta, M. Biselli, M. Bernardi, P. Caraceni ‐ Bologna

16.50‐17.05 Long term outcome of splanchnic vein thrombosis (SVT) in cirrhosis

M. Senzolo, N. Riva, F. Dentali, Soo Mee Bang, I. Martinelli, S. Schulman, A. Alatri, J. Beyer‐Westendorf, M.N.D. Di Minno, K. Rodriguez, M.T. Sartori, W. Ageno ‐ Padua, Varese, Seoul (South Korea), Milan, Hemilton (Canada), Cremona, Dresden (Germany)




17.05‐17.20 Screening and surveillance of esophageal varices: validation of Baveno VI criteria in a cohort of cirrhotic HCV patients

G. Tosetti, C. Della Corte, V. La Mura, A. Aghemo, R. D’Ambrosio, M. Colombo, M. Primignani ‐ Milan

17.20‐17.35 Young Investigators Awards Presenters for the 2 best oral communications Basic: M. Levrero, Rome, Lyon (France) ‐ G. Svegliati

Baroni, Ancona Clinical: A. Colli, Lecco ‐ V. Di Marco, Palermo

Presenters for the 2 best posters Basic: A. Alisi, Rome ‐ M. Carbone, Rozzano Clinical: S.S. Piano, Padua ‐ M.A. Iavarone, Milan

17.35 Closure of the Annual Meeting




Poster Session

Thursday, February 18th

N°1 Immunosuppression‐driven HBV reactivation in patients with resolved HBV infection correlates with a relevant risk of death and with evolution towards active chronical infection

A. Battisti, R. Salpini, L. Colagrossi, C. Alteri, M. Pollicita, A. Ricciardi, C. Cerva, G. Maffongelli, M. Lichtner, C. Mastroianni, K. Casinelli, M. Paoloni, M. Marignani, S. Maylin, C. Delaugerre, F. Morisco, N. Coppola, A. Marrone, A. Brega, S. Francioso, A. Venditti, T. Mari, E. Mazzoni, N. Iapadre, D. Di Paolo, C. Sarrecchia, L. Sarmati, M. Andreoni, G. Taliani, M. Angelico, C.F. Perno, V. Svicher ‐ Rome, Frosinone, Avezzano (AQ), Paris (France), Naples, L’Aquila

N°2 Risk factors of an early emergent hospital readmission due to a re‐infection in patients with cirrhosis after a recovery from a bacterial or fungal infection

F. Morando, S. Rosi, S. Piano, M.L. Stanco, E. Gola, A. Brocca, S. Fasolato, A. Sticca, C. Pilutti, M. Tonon, A. Romano, M. Cavallin, P. Angeli ‐ Padua

N°3 SerpinB3 up‐regulates hypoxia inducible factors‐1α and ‐2α in liver cancer cells through different mechanisms

S. Cannito, G. Villano, C. Turato, E. Morello, B. Foglia, E. Novo, S. Quarta, S. Colombatto, F. Lopitz‐Otsoa, T. Cardoso, M.L. Martínez‐Chantar, P. Pontisso, M. Parola ‐ Turin, Padua, Bizkaia (Spain)

N°4 HBsAg mutations correlated with HCC in vivo affect HBsAg release and favor cell proliferation in vitro

R. Salpini, M. Surdo, N. Warner, M. F. Cortese, C. Mirabelli, D. Colledge, S. Soppe, P. Saccomandi, M. Pollicita, R. Longo, S. Romano, G. Cappiello, A. Spanò, P. Trimoulet, H. Fleury, J. Vecchiet, N. Iapadre, A. Barlattani, A. Bertoli, T. Mari, C. Pasquazzi, G. Missale, C. Sarrecchia, E. Orecchini, A. Michienzi, M. Andreoni, S. Francioso, M. Angelico, F. Ceccherini‐Silberstein, S. Locarnini, C.F. Perno, V. Svicher Rome, Victoria (Australia), Paris (France), Bordeaux (France), Chieti, L’Aquila, Parma

N°5 Role of the protein kinase CK2 in the biology of cholangiocarcinoma cells

G. Di Maira, A. Gentilini, E. Rovida, D. Ottaviani, M. Ruzzene, F. Marra ‐ Florence, Padua

N°6 Role of AKI in patients with decompensated cirrhosis: preliminary results from a prospective study in two Italian University Hospitals

V. La Mura, G.M. Borroni, C. Lucidi, L. Severgnini, S. Sgobba, G. Gobbo, V. Monti, O. Riggio, M. Merli, G.L. Bonitta, F. Salerno ‐ Milan, Rome

N°7 Low Molecular Weight Heparin (LMWH) treatment does not increase the risk of bleeding after prophylactic endoscopic variceal band ligation in patients with cirrhosis

M. Bianchini, G. Cavani, A. Bonaccorso, L. Turco, A. Merighi, E. Villa, F. Schepis ‐ Modena

N°8 Telomerase extratelomeric effects in hepatocellular carcinoma: molecular targeting to impair tumoral networks in HCC

I. Martinozzi, N. Rosso, C. Tiribelli, D. Pascut ‐ Trieste

N°9 Validation of a method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common waiting list

A. Vitale, A.C. Frigo, P. Burra, P. Angeli, G. Zanus, U. Cillo Padua

N°10 ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS Study

A. Casadei Gardini, G. Marisi,L. Faloppi, E. Scarpi, F.G. Foschi, M. Iavarone, G. Lauletta, J. Corbelli, E. Tenti, F. Facchetti, C. della Corte, S. Tamberi, S. Cascinu, M. Scartozzi, D. Amadori, O. Nanni, P. Ulivi, G.L. Frassineti ‐ Meldola (FC), Ancona, Faenza (RA), Milan, Bari, Cagliari

N°11 Circulating microRNA in hepatocellular carcinoma as prognostic biomarkers

D. Pascut, H. Krmac, N. Mezzina, R. Patti, D. Licastro, S. Dal Monego, C. Abazia, L. Petraccia, F. Masutti, S.L. Crocè, R. Calligaris, C. Tiribelli ‐ Trieste

N°12 Incidence, predictors and outcomes of acute on chronic liver failure in outpatients with cirrhosis

S. Piano, M. Tonon, C. Pilutti, E. Vettore, M.L. Stanco, F. Morando, S. Rosi, A. Romano, E. Gola, A. Sticca, S. Fasolato, P. Angeli ‐ Padua

N°13 Laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma

U. Cillo, C. Ungaro, M. Moustafa, F. D’Amico, E. Gringeri, D. Bassi, D. Neri, G. Zanus, P. Burra, P. Angeli, F. Farinati, C. Aliberti, C. Mescoli, A. Vitale ‐ Padua

N°14 Renalase, a new protagonist of abnormal adrenergic activation in liver cirrhosis?

G. Sansoè, M. Aragno, R. Mastrocola, M. Parola ‐ Turin N°15 Proof of multiple mechanisms of solute‐free water retention

in experimental ascitic cirrhosis G. Sansoè, M. Aragno, R. Mastrocola, M. Parola ‐ Turin N°16 Efficacy and safety of treatment of acute nonmalignant

portal vein thrombosis with subcutaneous fondaparinux in patients with cirrhosis and marked thrombocytopenia

M. Tonon, S. Piano, D. Sacerdoti, F. Dalla Valle, L. Spiezia, M. Bolognesi, P. Simioni, P. Angeli ‐ Padua

N°17 Multimodality treatment of hepatocellular carcinoma: how field practice complies with international recommendations

M. Triolo, A. Sangiovanni, V. La Mura, M. Iavarone, C. Della Corte, A. Nicolini, G. Rossi, M. Colombo ‐ Milan

N°18 The balance between fibrosis and regeneration in chronic liver injury: the role of gender

M. Crescenzi, D. Bizzaro, D. Gabbia, M.T. Conconi, P. Burra, S. De Martin, F.P. Russo ‐ Padua

N°19 Adherence to BCLC treatment algorithm and survival predictors in single node HCC in Italy

C.Pozzan, M.A. Di Vasto, G. Maddalo, A.Vitale1, F. Trevisani, F. Farinati on behalf of the ITA.LI.CA investigators ‐ Padua, Bologna




N°20 The protease‐inhibitor SerpinB3 modulate survival and Wnt pathway of inflammatory human monocytes

A.Cappon, S. Quarta, A. Biasiolo, C. Turato, G. Villano, M. Ruvoletto, S. Fasolato, G.Zanus, U.Cillo, P. Pontisso ‐ Padua

N°21 In hepatocellular carcinoma miR‐494 up‐regulates the AKT/mTOR pathway and is involved in Sorafenib resistance

D. Pollutri, C. Patrizi, S. Marinelli, M. Ferracin, M. Negrini, M. Baron Toaldo, L. Bolondi, L. Gramantieri, F. Fornari Bologna, Ferrara

N°22 Development and validation of an on‐line web calculator for survival after trans‐arterial chemo‐embolization for hepatocellular carcinoma

A. Cucchetti, A. Cappelli, C. Sposito, F. Brunero, G. Cabibbo, S. Attardo, C. Mosconi, A.D. Pinna, R. Golfieri, V. Mazzaferro Bologna, Milan, Palermo

N°23 Feasibility and efficacy of sofosbuvir‐based antiviral therapy before liver transplantation to prevent HCV recurrence: a monocentric experience

S. Strona, S. Martini, D. Arese, M. Sacco, M.R. Torrani‐Cerenzia, A. Ottobrelli, R. Romagnoli, F. Tandoi, F. Balzola, D. Cocchis, S. Mirabella, G. Rizza, M. Salizzoni, M. Rizzetto, G.M. Saracco ‐ Turin

N°24 Exogenous administration of recombinant SERPINB3 inhibits cell reprogramming

E. Torchio, S. Quarta, S. Giulitti, C. Turato, A. Biasiolo, C. Luni, M. Ruvoletto, G. Villano, G.G. Giobbe, P. Pontisso, N. Elvassore Padua

N°25 P66shc and SerpinB3 interplay affects HCC clinical outcome and cell fate

M. Ruvoletto, S. Fasolato, G. Zanus, C. Turato, S. Quarta, L. Terrin, U. Cillo, A. Gatta, P. Pontisso ‐ Padua

N°26 PIVKA‐II is a useful tool for the diagnosis of early hepatocellular carcinoma

C. Saitta, G. Raffa, F. Casuscelli, S. Brancatelli, A. Alibrandi, G. Raimondo, T. Pollicino ‐ Messina

N.27 The Gut microbiota of cirrhotic patients with poor nutritional status: preliminary evidences

F.R. Ponziani , S. Pecere, V. Petito, F.P. Sterbini, A. Tortora, B.E. Annicchiarico, M. Siciliano, A. Palladini, C. Graziani, L. Masucci, M. Pompili, M. Sanguinetti, A. Gasbarrini and The GuLiver group ‐ Rome

N°28 Treatment of healthcare associated urinary tract infections: may an empirical broad spectrum antibiotic therapy improve survival? An analysis by a randomized trial

C. Lucidi, V. Di Gregorio, B. Lattanzi, R. Lacetera, M. Giusto, R. Iura, O. Riggio, M. Venditti, M. Merli ‐ Rome

N°29 Prevalence and risk factors for hepatitis C virus infection in a metropolitan area of Italy

F. Morisco, I. Loperto, T. Stroffolini, F.L. Lombardi, V. Cossiga, M. Guarino, A. De Feo, N. Caporaso ‐ Naples, Rome

N°30 Involvement of copper in the liver tumorigenesis C. Porcu, L. Antonucci , B. Barbaro, M. Arciello, C. Viscomi,

C. Balsano ‐ Rome N°31 Safety and efficacy of sofosbuvir‐based antiviral therapy

immediately after liver transplantation: a matched case‐control analysis

M. Sacco, S. Martini, D. Arese, S. Strona, F. Tandoi, D. Cocchis, S. Mirabella, G. Rizza, A. Ottobrelli, M. Salizzoni, M. Rizzetto, G. Saracco, R. Romagnoli ‐ Turin

N°32 All oral sofosbuvir‐based antiviral therapy in liver transplant recipients affected by moderate‐severe hepatitis C recurrence: predictors of viral response and survival

D. Arese, S. Martini, M. Sacco, S. Strona, D. Cocchis, S. Mirabella, G. Rizza, A. Ottobrelli, M.R. Torrani‐Cerenzia, F. Balzola, P. Magistroni, P. Moschini, A. Amoroso, M. Salizzoni, M. Rizzetto, R. Romagnoli, G.M. Saracco ‐ Turin

N°33 Expression of adrenomedullin in chronic inflammatory liver diseases

S. Sarcognato, F. Grillo, S. De Martin, A. Picciotto, V. Guzzardo, F.P. Russo, M. Guido ‐ Padua, Genoa

N°34 Lysosomal acid lipase activity is reduced in patients with cirrhosis and associated with surrogate indices of portal hypertension

U. Vespasiani Gentilucci, P. Gallo, A. Porcari, F. Vorini, L. Piccioni, G. Galati, A. De Vincentis, C. Dell'Unto, F. Piemonte, G. Tozzi, E. Riva, A. Picardi ‐ Rome

N.35 Accuracy Of Intestinal Permeability In Predicting The Development Of Complications In Patients With Liver Cirrhosis

F.R. Ponziani, V. Valenza, B.E. Annicchiarico, M. Siciliano, M. Pompili, A. Gasbarrini ‐ Rome

N°36 Analysis of hemodynamic effects of bosentan on portopulmonary hypertension in short‐term and medium‐term follow‐up: promising predictors of response to therapy?

A. Ottobrelli, A. Risso, W. Grosso Marra, S. Martini, F. Orzan, M. Torrani Cerenzia, F. Balzola, D. Arese, M. Sacco, S. Strona, D. Stradella, D. Libertucci, P.L. Omedè, A. Bissolino, D. Zema, G.M. Saracco, M. Rizzetto ‐ Turin

N°37 NS3 genetic variability in HCV genotype 1a isolates from liver tissues and serum samples of treatment‐ naïve patients with chronic hepatitis C

D. D’Aliberti, I. Cacciola, S. Benfatto, F. Mannino, R. Filomia, C. Beninati, C. Saitta, G. Raimondo, T. Pollicino ‐ Messina

N°38 Erectile dysfunction in patients with liver cirrhosis S. Maimone, G. Oliva, A. Di Benedetto, R. Filomia, G. Caccamo,

C. Saitta, I. Cacciola, G. Squadrito, G. Raimondo ‐ Messina N°39 Early onset of hyperthension and serum electrolite changes

as potential predictive factors of activity in advanced HCC treated with sorafeinb: results from a retrospective analysis of HCC‐AVR group

A. Casadei Gardini, E. Scarpi, G. Marisi, G.F. Foschi, G. Donati, E. Giampalma, L. Faloppi, M. Scartozzi, N. Silvestris, M. Bisulli, J. Corbelli, A. Gardini, G. La Barba, L. Veneroni, S. Tamberi, S. Cascinu, G.L. Frassineti ‐ Meldola (FC)

N°40 Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST‐HCV, a large regional database

V. Di Marco, G. Squadrito, A. Davì, G. Scifo, M. Russello, R. Volpes, A. Montineri, S. Madonia, T. Prestileo, A. Digiacomo, N. Tripodi, G. Bertino, F. Tinè, A. Licata, A. Magro, B. Cacopardo, A. Salvo, G. Mannino, I. Scalisi, P. Colletti, L. Guarneri, V. Portelli, F. Cartabellotta, G. Raimondo and A. Craxì on behalf of RESIST‐HCV (Rete Sicilia Selezione Terapia –HCV) ‐ Palermo

N°41 Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma

A. Zanetto, A. Ferrarese, E. Nadal, I. Bortoluzzi, E. Campello, U. Cillo, F. Farinati, G. Germani, F.P. Russo, L. Spiezia, P. Simioni, P. Burra, M. Senzolo ‐ Padua




N°42 Prevalence and features of chronic viral hepatitis and HIV/viral hepatitis coinfections in Italian prisons

C. Stasi, C. Silvestri, E. Fanti, G. Martino, G. Bazzerla, F. Ferrari, M. Grignani, S. Libianchi, A.M. Pagano, F. Scarpa, T. Di Fiandra, F. Voller – Florence, Treviso, La Spezia, Perugia, Rome, Salerno, Empoli

N°43 Angiopoietin‐like4 is associated with lipid metabolism and severe fibrosis in non‐diabetic patients with non‐alcoholic fatty liver disease

C. Rosso, M. Gaggini, C. Saponaro, M. Marietti, G.P. Caviglia, F. Carli, E. Buzzigoli, M.L. Abate, A. Smedile, G.M. Saracco, A. Gastaldelli, E. Bugianesi ‐ Turin, Pisa

N°44 Unexpected very early atherosclerotic and cardiac damage in patients undergoing liver transplantation

G. Pisano, M. Orlandi, M.F. Donato, S. Zannoni, C. Bertelli, G. Oberti, L. Caccamo, M. Colombo, S. Fargion, A.L. Fracanzani Milan

N°45 Liver and adipose tissue interplay through the up‐regulation of the Th17 pathway

C.M. Chackelevicius; P. Giraudi, S.E. Gambaro, S. Palmisano, M. Giuricin, N. Demanzini, D. Bonazza, F. Zanconati, C. Tiribelli, N. Rosso ‐ Trieste

N°46 Percutaneous electrochemotherapy of malignant main portal veins thrombosis: a prospective case series

L. Tarantino, G. Busto, A. Nasto, R. Fristachi, L. Cacace, M. Talamo, P. Ambrosino, P.Gallo, A. Sullo, P.Tarantino, C. Accardo ‐ Salerno, Naples, Rome, Pagani (SA), Nocera (SA)

N°47 Prediction of post‐operative liver failure in cirrhotic patients undergoing surgical resection for hepatocellular carcinoma: the role of liver stiffness measured by acoustic radiation force impulse and the proposal for a new mathematical model score

C. Iegri, A. De Santis, M. Lupo, G. Grazi, M. Rossi, G. Gallusi, M. Forlino, S. Di Filippo, F. Melandro ‐ Rome

Friday, February 19th

N°1 Impact of different Sofosbuvir‐based Direct Acting Antiviral (DAA) regimen in elderly cirrhotic patients: a real world experience from CLEO group

A. M. Pellicelli, V. Pace Palitti, P. Vignally, A. Moretti, P. Tarquini, G. Scifo, V. Messina, A. Ascione, A. Izzi, C. D'Ambrosio, R. Villani, L. Fondacaro, L. Fontanella, P. Guarascio, L. Alessio, L. Miglioresi, E. D'Amico, G.M. Ettorre, M. Marignani, P. Begini, G. Cerasari, A. Barlattani, O. Armignacco, G. Barbarini and for the CLEO Group ‐ Rome, Pescara, Genoa, Teramo, Siracusa, Caserta, Naples, Penne (PE), Viterbo, Pavia

N°2 Low‐dose ribavirin seems to have no impact on response to DAA‐regimens for HCV therapy in advanced liver disease

G. Valente, G. Piai ‐ Caserta N°3 Lean‐non alcoholic fatty liver disease (NAFLD) with central

visceral obesity identifies patients with more severe disease R. Lombardi, L. Mensi, G. Pisano, P. Dongiovanni, C. Bertelli,

E. Fatta, L. Valenti, S. Fargion, A.L. Fracanzani ‐ Milan N°4 Clinical determinants of fibrosis progression in an Italian

prospective cohort of patients with nonalcoholic fatty liver disease

R. Lombardi, S.Pelusi, E. Hyseni, V. Borroni, A.L. Fracanzani, S. Fargion, L. Valenti ‐ Milan

N°5 Differential inflammatory phenotypes upon genetic or pharmacologic inactivation of indoleamine dioxygenase in experimental steatohepatitis

E. Vivoli, B. Piombanti, F. Fallarino, F. Marra ‐ Florence, Perugia N°6 Clinical outcome in hospitalized cirrhotic patients with

bacterial infections treated with empirical or antibiogram‐guided therapy

G. Caccamo, S. Maimone, R. Filomia, M.S. Franzè, S. Tomeo, R. Spinella,T. Lembo, A. Alibrandi, P. Mondello, C. Saitta, I. Cacciola, G. Squadrito, G. Raimondo ‐ Messina

N°7 Functionalized polymers to target SerpinB3 in hepatoma cells S. Quarta, S. Chiarani, J. Baseggio, P. Pontisso, P. Caliceti ‐

Padua

N°8 Sorafenib in clinical practice: pooled analysis of two

prospective observational studies in hepatocellular carcinoma (HCC)

G.G. Di Costanzo, S. D'Angelo, T. Zolfino, V. Lorusso, V. Montesarchio, G. de Stefano, R. Sacco, A.F. Attili, A. Benedetti, D. Sansonno, L. Giannitrapani, A. Buonadonna, P. Giovanis, G. Cabibbo, F. De Vita, P. Carucci, M. Pirisi, M. Moscovici, S. Pisconti, B. Daniele ‐ Naples, Avellino, Cagliari, Bari, Pisa, Rome, Ancona, Palermo, Aviano (PN), Feltre (BL), Turin, Novara, Milan, Taranto, Benevento

N°9 Peripheral NK cells in patients with HCV recurrence after liver transplantation during interferon‐free antiviral therapy

A. Zanetto, A. Ferrarese, A. Shawkat, S. Shalaby, C. Bergamo, E. Franceschet, I. Bortoluzzi, E. Nadal, M. Gambato, G. Germani, M. Senzolo, E. Gringeri, G. Zanus, P. Boccagni, U. Cillo, P. Burra, F. P. Russo ‐ Padua

N°10 Clinical and virological characteristics of HIV and HCV co‐infected versus HCV monoinfected patients: a real‐life evaluation in the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort

P. Colombatto, E. Biliotti, D. Palazzo, A. Ciancio, B. Del Pin, V. Rizzo, G. Brancaccio, M.C. Pasetto, E. Castelli, D. Ieluzzi, E. Franceschet, S. Storato, M. Margotti, E. Castelli, S. Palladini, D.C. Amoruso, A. Buggio, S. Madonia, C. Cerva, D. Bartolozzi, F. Castelli, R. Gulminetti, G. Mazzella, L. Bolondi, F. Baldelli, M. Angelico, R. Bruno, A. Gori, G. D'Adamo, G. Leandro, J. Vecchiet, A. Picardi, V. Vullo, M. Libanore, N. Coppola, A. Grieco, L. Raffaele, M. Mondelli, R. Cauda, M. Galli, G. Di Perri, A. Floreani, A. D'Arminio Monforte, M.G. Quaranta, L. Kondili, S. Rosato, M. Mirra, M. E. Tosti, S. Vella and ISS&AISF&SIMIT Collaborating Group in PITER available in www.piter.iss.it ‐ Pisa, Rome, Turin, Florence, Naples, Cagliari, Padua, Verona, Bologna, Milan, Gragnano (NA), Palermo, Florence, Brescia, Pavia, Perugia, Monza (MB), Salerno, Castellana Grotte (BA), Chieti, Ferrara, Lecco




N°11 Laparoscopic thermal ablation of hepatocellular carcinoma unsuitable for percutaneous treatments or hepatic resection: a comparative study

M. Barabino, R. Santambrogio, J. Chiang, F. Meloni, S. Bruno, M. Zuin, E. Opocher ‐ Milan, Madison (USA), Como, Rozzano (MI)

N°12 HBV‐HDV co‐infection constrains HBV genetic evolution in HBsAg

L. Colagrossi, R. Scutari, R. Salpini, A. Battisti, M. Pollicita, A. Bertoli, C. Minichini, P. Trimoulet, H. Fleury, E. Nebuloso, M. De Cristofaro, G. Cappiello, A. Spanò, V. Malagnino, L. Sarmati, T. Mari, A. Barlattani, N. Iapadre, M. Lichtner, C. Mastroianni, I. Lenci, L. Baiocchi, C. Pasquazzi, G.M. De Sanctis, A.G. Lanza, M. Stanzione, G. Stornaiuolo, M. Marignani, M. Andreoni, M. Angelico, C.F. Perno, N. Coppola, V. Svicher ‐ Rome, Naples, Bordeaux (France), L’Aquila

N°13 Allosteric modulation of mGlu5 receptors by MPEP protects against hepatic cold ischemia and reperfusion injury

C. Berardo, L.G. Di Pasqua, V. Rizzo, P. Richelmi, F. Nicoletti, A. Ferrigno, M. Vairetti ‐ Pavia, Pozzilli (IS), Rome

N°14 Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: biological and clinical features, and outcome

P. Lampertico, G. Grossi, A. Loglio, M. Viganò, F. Facchetti, F. Invernizzi, M. Iavarone, A. Sangiovanni, M. Colombo ‐ Milan

N°15 Diagnostic performance of point share wave elastography (pSWE) in comparison with transient elastography performed by Fibroscan® (TE) and non‐invasive scores of fibrosis in primary biliary cirrhosis (PBC)

F. Saffioti, D. Roccarina, M. Rosselli, M. Pinzani, A. Marshall, D. Thorburn ‐ London (UK), Messina, Rome

N°16 DPPIV/CD26 and SerpinB3 interaction affects metabolism and clinical outcome in hepatocellular carcinoma

M. Ruvoletto, S. Fasolato, E. Trevellin, M. Granzotto, G. Zanus, E. Babetto, L. Terrin, M. Battocchio, F. Ciscato, C. Turato, U. Cillo, P. Pontisso, R. Vettor ‐ Padua

N°17 ITPA deficiency does not predict anaemia during Ribavirin containing DAA all oral regimens for HCV

S. De Nicola, E. Galmozzi, A. Aghemo, R. D’Ambrosio, E. Degasperi, M. Borghi, M. Colombo ‐ Milan

N°18 Efficacy and safety of percutaneous laser ablation therapy for treatment of large HCC

S. Camera, G.G. Di Costanzo, R.Tortora, L. Addario , F. Lampasi, M.T. Tartaglione, V. Cossiga, L. Donnarumma, N. Caporaso, F. Morisco ‐ Naples

N°19 Monitoring liver steatosis by means of a new ultrasound imaging system (Steatometer) in HCV treated patients

F. Faita, C. Avigo, L. Cini, N. Di Lascio, A. Salvati, B. Coco, P. Colombatto, N. Martini, D. Chiappino, F. Bonino, M.R. Brunetto ‐ Pisa, Massa

N°20 Plasma ribavirin concentration in HCV cirrhotic patients treated with Direct Antiviral Agents (DAAs)

E. Biliotti, D. Palazzo, L. Lionetto, P. Perinelli, R. Esvan, C. Franchi, G. Iaiani, P. Maida, C. Pasquazzi, M. Spaziante, P. Rucci, M. Simmaco, G. Taliani ‐ Rome, Bologna

N°21 Treatment with direct acting antiviral agents‐based regimen in HCV patients with advanced liver disease: analysis of an Italian multicenter observational study

F. Conti, A. Scuteri, R. Di Donato, G. Lazzarini, A. Porro, P. Muratori, I. Serio, F. Buonfiglioli, L. Badia, A. Lanzi, M. Mastroroberto, L. Appolloni, M. Morotti, M.C. Morelli, F.G. Foschi, G. Verucchi, S. Brillanti, C. Crespi, M. Lenzi, G. Mazzella, P. Andreone ‐ Bologna, Faenza (RA)

N°22 Meld score predicts outcome of patients with advanceed hepatocellular carcinoma treated with Sorafenib

A. Casadei Gardini, L. Faloppi, G. Marisi, F.G. Foschi, G. Donati, M. Scartozzi ‐ Meldola (FC)

N°23 Etiology of chronic liver disease and HCC biomarkers G. Ricco, D. Cavallone, C. Cosma, G.P. Caviglia, F. Oliveri,

A. Biasiolo, M.L. Abate, M. Plebani, A. Smedile, F. Bonino, P. Pontisso, M.R. Brunetto ‐ Pisa, Padua, Turin

N°24 Presentation and outcome in patients with drug induced liver injury: a three‐year experience

C. Bergamo, G. Germani, D. Bizzaro, E. Nadal, I. Bortoluzzi, A. Ferrarese, A. Zanetto, S. Shalaby, M. Senzolo, F.P. Russo, P. Burra ‐ Padua

N°25 Extrahepatic autoimmunity in patients with autoimmune hepatitis (AIH)

N. Cazzagon, I. Franceschet, L. Perini, C. Mangini, L. Costa, A. Floreani ‐ Padua

N°26 Primary biliary cholangitis in elderly patients I. Franceschet, N. Cazzagon, C. Mangini, L. Perini, A. Floreani

Padua N°27 Clinical and virological profile of patients with diagnosed HCV

chronic infection in Italy: data from PITER cohort study ISS and AISF and SIMIT PITER collaborating Group available in

www.iss.it/piter ‐ Istituto Superiore di Sanità, Rome N°28 The role of serum alphafetoprotein determination in HCV‐

cirrhosis after antiviral treatment C. Della Corte, R. D'Ambrosio, N. Piazza O Sed, A. Sangiovanni,

A. Aghemo, M. Iavarone, S. De Nicola, M. Colombo ‐ Milan N°29 Clinical and functional changes associated with the sustained

virological response after treatment of genotype‐1HCV recurrence in liver transplant recipients: does sofosbuvir differ from peg‐interferon based therapy?

I. Lenci, M. Milana, F. Santopaolo, P. Rossi, S. Francioso, C. Masetti, D. Di Paolo, S. Cucchiarelli, F. De Leonardis, A. Bosa, M. Angelico, L. Baiocchi ‐ Rome

N°30 Further increase in biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury by obeticholic acid, a farnesoid‐X‐receptor agonist

L.G. Di Pasqua, C. Berardo, V. Rizzo, L. Adorini, P. Richelmi, M. Vairetti, A. Ferrigno ‐ Pavia, San Diego (USA)

N°31 Treatment of high baseline viral load chronic hepatitis B using sequential therapy with entecavir and PEG‐IFN

L. Boglione, C.S. Cardellino, A. De Nicolò, J. Cusato, G. Cariti, G. Di Perri, A. D’Avolio ‐ Turin




N°32 Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients

M.C. Sorbo, F.P. Antonucci, M. Manuelli, I. Lenci, D. Sforza, L. Carioti, M.C. Bellocchi, V. Cento, D. Di Paolo, F. De Leonardis, M. Milana, T. Manzia, G. Tisone, M. Angelico, C.F. Perno, F. Ceccherini‐Silberstein ‐ Rome

N°33 Striking gender differences in emotional intelligence among HCV cirrhotic patients

G. Taliani, E. Biliotti, D. Palazzo, P. Perinelli, M. De Angelis, R. Esvan, L. Fariselli, L. Fontanelli Sulekova, C. Franchi, G. Iaiani, C. Marsiglia, M. Rivano Capparuccia, M. Santori, M. Spaziante, F. Tamburini, P. Rucci ‐ Rome, Bologna

N°34 High‐powered microwaves (MWS) ablation of intermediate Hepatocellular Carcinoma (HCC) in cirrhosis: a multicenter, prospective study

A. Giorgio, P. Gatti, C. Coppola, G. Iaquinto0, B. Santoro, F. Amendola, V. Giorgio ‐ Naples, Fasano (BR), Avellino, Piedimonte Matese (CE), Tortorella (SA), Rome

N°35 Higher simeprevir plasma exposure when co‐administered with sofosbuvir leads to higher risk of dermatological toxicity

A. De Nicolò, L. Boglione, F. Favata, A. Ariaudo, J. Cusato, C.S. Cardellino, C. Carcieri, G. Di Perri, A. D’Avolio ‐ Turin

N°36 Impact of DAA therapy on health‐related quality of life in liver transplanted patients. Is there a role for ribavirin?

R. Lionetti, A. Palummieri, C. Taibi, E. Medici, M. Montalbano, U. Visco Comandini, L. Loiacono, V. Puro, G.M. Ettorre, M. Giulianelli, G. D'Offizi ‐ Rome

N°37 Coronary microvascular dysfunction in patients with decompensated cirrhosis: another tool for understanding cirrhotic cardiomyopathy?

A. Ferrarese, F. Tona, G. Famoso, E. Ferrazzi, E. Segato, F. Folino, S. Tellatin, F.P. Russo, G. Germani, A. Zanetto, S. Iliceto, P. Burra, M. Senzolo ‐ Padua

N°38 Are cirrhotic patients awaiting liver transplantation protected against vaccine preventable diseases?

M. Tran Minh, A. Mazzola, R. Pais, P. Lebray, D. Bernard, C. Goumard, Y. Calmus, F. Conti ‐ Paris (France), Novara, Palermo

N°39 Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection

D.G. Pacini, S. Onali, C. Balestrieri, F. Figorilli, S. Casu, G. Serra, L. Chessa ‐ Cagliari

N°40 Pre‐emptive post‐transplant HCV treatment with ifn‐free daa: preliminary results from a pilot study

L. Pasulo, C. Di Benedetto, C. Mazzarelli 2, C. Iegri, F. Mangiola, G. Perricone, R. Viganò, M. Colledan, L. De Carlis, A. Corti, E. Mazza, A. De Gasperi, M. Marchesi, F. Donato, S. Fagiuoli, L. Belli ‐ Bergamo, Milan

N°41 Hepatitis C core antigen assay for the monitoring of treatment with Direct Antiviral Agents in patients with chronic hepatitis C

E. Loggi, C. Cursaro, A. Scuteri, R. Vukotic, E. Grandini, M. Margotti, V. Guarneri, M. Stanzani, S. Galli, G. Furlini, C. Galli, M.P. Landini, P. Andreone ‐ Bologna, Rome

N°42 Transition of pediatric liver transplanted recipients to Adult Healthcare Service: a single center cohort

A. Ferrarese, G. Germani, M. Cananzi, A. Zanetto, C. Bergamo, S. Shalaby, E. Nadal, I. Bortoluzzi, M. Senzolo, F.P. Russo, U. Cillo, P. Burra ‐ Padua

N°43 Hippocampal axis dysfunction evaluation by Rey‐Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment

S. Casu, F. Figorilli, F. Di Stefano, S. Onali, C. Balestrieri, G. Serra, M. Puligheddu, L. Chessa ‐ Cagliari

N°44 Liver transplantation in hiv‐positive patients: the initial experience

C. Di Benedetto, C. Iegri, L. Pasulo, G. Travi, C. Moioli, M. Colledan, L. De Carlis, C. Mazzarelli, G. Cologni, A. Corti, E. Mazza, M. Marchesi, A. De Gasperi, I. Mangoni, F. Mangiola, L. Belli, S. Fagiuoli, M. Puoti ‐ Bergamo, Milan

N°45 Accuracy of the latest release of a 2D shear wave elastography method for staging liver fibrosis in patients with chronic hepatitis C: preliminary results

G. Ferraioli, L. Maiocchi, R. Lissandrin, C. Tinelli, C. Filice ‐ Pavia N°46 Survival in patients with hepatocellular carcinoma and portal

vein thrombosis G. Pisano, A. Sangiovanni, C. Bertelli, S. Vavassori, M. Iavarone,

N. O. S. Piazza, M. Colombo, S. Fargion, A.L. Fracanzani ‐ Milan N°47 Hepatitis B core‐related antigen levels during nucleos(t)ide

analogues or pegylated‐interferon treatment in patients chronically infected with HBV genotype‐D

G.P. Caviglia, M.L. Abate, D. Noviello, A. Olivero, C. Rosso, G. Troshina, A. Ciancio, G.M. Saracco, A. Smedile ‐ Turin




INFORMAZIONI GENERALI

Sede: Aula Magna Università di Roma “Sapienza” P.le A. Moro, 5 00185 ROMAwww.uniroma1.it/ateneo/dove‐siamo

Provider E.C.M. (ID 1547): A.I.S.F. ‐ Associazione Italiana per lo Studio del Fegato Via Alfredo Catalani, 39 00199 ROMA Tel. e Fax: 06‐86399303 E‐mail: [email protected]

Segreteria Organizzativa: SPAZIO CONGRESSI S.r.l. Via Alfredo Catalani, 39 00199 ROMA Tel. e Fax: 06‐86204308 E‐mail: [email protected]

www.webaisf.org

Modalità di partecipazione: Socio A.I.S.F. (in regola con il versamento delle quote associative): partecipazione gratuita Non Socio A.I.S.F.: € 260,00 (inclusa IVA 22%)

e comprende: Partecipazione ai lavori congressuali Kit congressuale Coffee breaks Colazioni di lavoro Digestive and Liver Disease

Nuovi Soci A.I.S.F. Per accedere in qualità di Socio A.I.S.F. all’Evento Formativo e, pertanto, per usufruire della quota agevolata, è necessario iscriversi all’A.I.S.F. la cui modulistica è presente sul sito: www.webaisf.org o contattare direttamente la Segreteria A.I.S.F. L’iscrizione all’A.I.S.F. dà diritto alla partecipazione gratuita alle Riunioni Istituzionali “Riunione Generale Annuale”, “Riunione Monotematica” e “Special Conference”, all’abbonamento gratuito alla rivista Digestive and Liver Disease, all’utilizzo gratuito dell’App di A.I.S.F. ed a ricevere qualsiasi informazione relativa all’attività dell’Associazione.

Modalità di pagamento (Non Socio A.I.S.F.): tramite bonifico bancario intestato alla Segreteria Organizzativa “SPAZIO CONGRESSI S.r.l.” tratto sulla BANCA INTESA SANPAOLO S.p.A. ‐ Filiale di Roma 03 Montesacro n. 00453 ‐ IBAN: IT 77 Q 03069 03202 100000031635. N.B.: Le iscrizioni prive di compilazione e spedizione della Scheda di Pre‐Iscrizione unitamente alla copia del pagamento non saranno prese in considerazione e, pertanto, considerate nulle. Cancellazione e rimborsi: Le cancellazioni pervenute entro il 08 Febbraio 2016, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell’importo versato, detratto l’importo di € 15,00 per spese amministrative. Superata la data del 8 Febbraio 2016 non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell’Evento.

E.C.M. ‐ Educazione Continua in Medicina e Destinatari Attività Formativa L’Evento Formativo ID 1547‐145825 è accreditato per n. 350 partecipanti, per le seguenti categorie professionali: Biologo e Medico Chirurgo specializzate per le seguenti discipline: Gastroenterologia; Malattie Infettive; Medicina Interna; Chirurgia Generale; Microbiologia e Virologia; Medicina Generale (Medici Di Famiglia); con N° 2,4 Crediti. Obiettivo Formativo E.C.M. ‐ Educazione Continua in Medicina: Epidemiologia ‐ Prevenzione e Promozione della Salute con Acquisizione di Nozioni Tecnico‐Professionali.




Procedure di attestazione della partecipazione e valutazione dell’apprendimento ai fini E.C.M. ‐ Educazione Continua in Medicina: Ogni partecipante potrà conseguire i crediti assegnati all’Evento rispettando i seguenti requisiti:

compilazione dell’Autodichiarazione di apprendimento completa di Anagrafica partecipante; partecipazione all’80% dell'intera attività formativa con verifica tramite “badge elettronico” in entrata e in

uscita. Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all’attestato di partecipazione. L’attestato E.C.M. verrà spedito a tutti i partecipanti che ne avranno diritto dopo il termine dell’Evento all’indirizzo di posta elettronica riportato sul questionario.

PROGRAMMA.ANN.2016.ver.07.del 26 Gen 2016.final · Aula Magna, Università di Roma “Sapienza”...

Documents

Transcript of PROGRAMMA.ANN.2016.ver.07.del 26 Gen 2016.final · Aula Magna, Università di Roma “Sapienza”...